Document:

Retention Bonus Agreement

  
 Exhibit 10.84

  
 PINNACLE SYSTEMS, INC. 
  
 Retention Bonus Agreement 
  
 Pinnacle Systems, Inc. (the “Company”) hereby grants you, Scott E. Martin (the “Executive”), a retention bonus of $100,000 (the “Retention Bonus”), subject to the
provisions of Appendix A attached hereto. The date of this Retention Bonus Agreement (the “Agreement”) is March 18, 2005. 
  
 IMPORTANT: 
  
 Your signature below indicates your agreement and understanding that this Agreement is subject to all of the terms and conditions contained in Appendix A.
PLEASE BE SURE TO READ ALL OF APPENDIX A, WHICH CONTAINS THE SPECIFIC TERMS AND CONDITIONS OF THIS AGREEMENT. 

  

					
	PINNACLE SYSTEMS, INC.	 	 	 	EXECUTIVE:
			
	 /s/ Patti S. Hart
	 	 	 	 /s/ Scott E. Martin

	 Patti S. Hart
	 	 	 	 Scott E. Martin

	 Chairman and Chief Executive Officer
	 	 	 	 
			
	 Date: March 18, 2005
	 	 	 	 Date: March 18, 2005

  

  
 APPENDIX A

  
 TERMS AND CONDITIONS OF RETENTION BONUS

  
 1. Award. The Company hereby awards a Retention
Bonus to the Executive equal to $100,000, subject to all of the terms and conditions in this Agreement. 
  
 2. Company’s Obligation to Pay. Provided that the Retention Bonus is earned, it shall be payable by the Company 30 days after the
“Payment Triggering Event Date” which is defined as the earlier of: 
  
 (A) The “Closing” as defined in that certain Agreement and Plan of Merger by and among Avid Technology, Inc., Highest Mountain Corporation and Pinnacle Systems, Inc., dated as of March 20, 2005 (the
“Merger Agreement”); 
  
 (B) The
termination of the Merger Agreement pursuant to Article VIII thereof; or 
  
 (C) Termination of the Executive “without cause” or for Executive’s voluntary resignation for “good reason” (each as defined in that certain Change of Control Severance Agreement dated May 10,
2004 between Executive and the Company (the “Change of Control Agreement”)). 
  
 To earn the Retention Bonus, the Executive must remain employed by the Company until the Payment Triggering Event Date. The Retention Bonus is a one-time bonus payment and creates no obligation by the Company to make
further similar bonus payments. 
  
 3. Withholding of
Taxes. All payments made pursuant to this Agreement shall be subject to withholding of applicable taxes. 
  
 4. No Effect on Employment or Service. Subject to Executive’s Employment Offer Letter entered into with the Company on April 9, 2004 (the
“Offer Letter”) and the Change of Control Agreement, this Agreement does not alter Executive’s
at-will employment status. Executive’s employment or other service with the Company and its subsidiary companies remains on an at-will basis only. Accordingly, the terms of Executive’s employment or service with the Company and its
subsidiary companies shall be determined from time to time by the Company or the subsidiary of the Company employing Executive, as the case may be, and the Company or the subsidiary shall have the right, which is hereby expressly reserved, to
terminate or change the terms of the employment or service of the Executive at any time for any reason whatsoever, with or without good cause, subject to the Offer Letter and the Change of Control Agreement. 
  
 5. Binding Agreement. Subject to the limitation on the transferability
of this grant contained herein, this Agreement shall be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto. 
  
 6. Captions. Captions provided herein are for convenience only and are not to serve as a basis for interpretation or
construction of this Agreement. 
  

 7. Agreement Severable. In the event that any provision in this Agreement shall be held invalid or
unenforceable, such provision shall be severable from, and such invalidity or unenforceability shall not be construed to have any effect on, the remaining provisions of this Agreement. 
  
 8. Modifications to the Agreement. This Agreement constitutes the entire understanding of the parties on the subjects
covered. The Executive expressly warrants that he is not accepting this Agreement in reliance on any promises, representations, or inducements other than those contained herein. Modifications to this Agreement can be made only in an express written
contract executed by a duly authorized officer of the Company. 
  
 9. Notice of Governing Law. This Retention Bonus shall be governed by, and construed in accordance with, the laws of the State of California without regard to principles of conflict of laws. 
  

 -2-Commercialization and Supply Agreement

 EXHIBIT 10.143 
  
 CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN FILED SEPARATELY WITH THE U.S.
SECURITIES AND EXCHANGE COMMISSION 
  
 AMENDMENT NO. 1 TO

 LICENSE, COMMERCIALIZATION AND SUPPLY AGREEMENT 
  
 THIS AMENDMENT (the “Amendment”), dated as of April 30, 2005 (the “Amendment Effective
Date”), by and between Indevus Pharmaceuticals, Inc. (“Indevus”) and Odyssey Pharmaceuticals, Inc. (“Odyssey”), amends that certain License, Commercialization and Supply Agreement, dated as of April 6, 2004
(the “Agreement”), by and between Indevus and Odyssey. 
  
 W I T N E S S E T H: 
  
 WHEREAS, the
Copromotion Period ended on November 28, 2004; and 
  
 WHEREAS, the Parties desire to resolve and settle between themselves certain issues that have arisen under the Agreement and to enter into certain other agreements between them, all upon the terms and subject to the conditions set
forth in this Amendment. 
  
 NOW, THEREFORE, in
consideration of the premises contained herein, and for other good and valuable consideration, the adequacy and receipt of which are hereby acknowledged, the Parties hereto agree as follows: 
  

	 	1.	Definitions and Section References. 

  
 Capitalized terms not defined in this Amendment shall have the meaning ascribed to them in the Agreement. 
  

	 	2.	Product Expenses. 

  
 Subject to Indevus’s satisfaction of its obligations under Paragraph 5 of this Amendment, the Parties agree that Indevus has satisfied its obligation
to pay the Indevus Cost Share and that Indevus has no responsibility or obligation for Product Expenses incurred by the Parties after November 28, 2004. 
  

	 	3.	Sublicensing Royalties. 

  
 Notwithstanding the provisions of Sections 6.3 – 6.5 of the Agreement, the Parties agree that Odyssey shall pay Sublicensing Royalties to Indevus,
(a) covering the period from December 1, 2004 to March 31, 2005, on May 2, 2005, and (b) covering each calendar month commencing on April 1, 2005, on the twentieth (20th) day of the calendar month immediately following such calendar month, calculated based upon gross sales of Product as recognized by Odyssey less deductions
aggregating [*]% of gross sales of Product recognized, for the applicable period as recognized by Odyssey, multiplied by [*] percent ([*]%), until Odyssey has paid Indevus an aggregate amount equal to $[*] 
  

	[*]	CONFIDENTIAL TREATMENT REQUESTED 

 (the “Reversion Threshold”). The Parties acknowledge and agree that the Reversion Threshold is based on
gross sales of Product $[*], less deductions from such gross sales of $[*]. Until Odyssey has paid Indevus an amount equal to the Reversion Threshold, no further deductions, whether or not taken, allowed or granted by Odyssey prior to or after the
date of this Amendment, shall be taken against gross sales of Product recognized by Odyssey. 
  
 Notwithstanding the foregoing, in the event of any assignment by Odyssey of the Agreement or any of its rights under the Agreement, or in the event of any transfer or sale of Odyssey’s business or all or
substantially all of its assets relating to Product or in the event of a merger, consolidation, change in control or similar corporate transaction relating to Odyssey or Parent (each, a “Transaction”), any unpaid Sublicensing Royalties
pursuant to this Paragraph 3 shall become immediately due and payable upon the effectiveness of such assignment or Transaction and Odyssey shall simultaneously pay Indevus an amount equal to the difference between the Reversion Threshold and the
aggregate Sublicensing Royalties previously paid by Odyssey to Indevus pursuant to this Paragraph 3. 
  
 Gross sales of Product is agreed to be gross sales as recognized by Odyssey using Odyssey’s method of recognizing gross sales until GAAP permits
Odyssey to recognize gross sales based upon shipments, at which time Odyssey will use the method as stated in Section 1.63 of the Agreement to compute Net Sales, except that in any event, deductions from gross sales will be [*]% until gross
sales of Product of $[*], as specified in Paragraph 3 of this Amendment, has been recognized by Odyssey. 
  

	 	4.	Third Party Royalties. 

  
 Notwithstanding the provisions of Sections 6.3 – 6.5 of the Agreement, the Parties agree that Odyssey shall pay Third Party Royalties to Indevus, in
an amount equal to [*] percent ([*]%) of the Sublicensing Royalties paid by Odyssey to Indevus pursuant to Paragraph 3 above for the applicable period, at the same time that such Sublicensing Royalties are due and payable to Indevus
under Paragraph 3, until Odyssey has paid Indevus Sublicensing Royalties under Paragraph 3 equal to the Reversion Threshold. Thereafter, Odyssey shall revert to paying Third Party Royalties to Indevus, calculated based upon Sublicensing Royalties
paid to Indevus, in accordance with Section 6.4 of the Agreement. 
  

	 	5.	Phase IV Clinical Trials. 

  
 Notwithstanding the provisions of Section 1.83(e) of the Agreement, Indevus agrees to pay Odyssey an amount equal to [*] percent ([*]%) of
the Sublicensing Royalties payable by Odyssey to Indevus pursuant to Paragraph 3 above until the Reversion Threshold is paid by Odyssey to Indevus, as a contribution towards the cost of those Phase IV post-approval marketing studies listed on
Appendix A and as may be agreed to between the Parties (the “Phase IV Studies”). Odyssey shall conduct the Phase IV Studies in accordance with the Agreement. The Parties agree that the amounts payable by Indevus pursuant to
this Paragraph 5 ($[*] in the aggregate) shall be due and payable on a monthly basis, with the first payment due on May 2, 2005, provided that such payments shall be effected in the form of an offset against the Sublicensing Royalties payable
by Odyssey to Indevus pursuant to Paragraph 3 of this Amendment, including against any Sublicensing Royalties paid by Odyssey to Indevus pursuant to the second paragraph of Paragraph 3 of this Amendment. 
  

	[*]	CONFIDENTIAL TREATMENT REQUESTED 

	 	6.	Satisfaction of Obligations. 

  
 The Parties agree that subject to and contingent upon Odyssey’s payment of Sublicensing Royalties in an amount equal to the Reversion Threshold and
the Third Party Royalties related thereto pursuant to Paragraphs 3 and 4 above, Odyssey has satisfied its obligations under the Agreement to pay Third Party Royalties and Sublicensing Royalties for the Copromotion Period, subject to Indevus’s
rights under Section 6.6 of the Agreement. 
  

	 	7.	Other. 

  
 Except as expressly amended by this Amendment, all of the provisions of the Agreement shall remain in full force and effect and all references to the
Agreement from and after the Amendment Effective Date shall be deemed to include this Amendment. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and
the same instrument. 
  
 [Remainder of this page intentionally left
blank] 

 IN WITNESS WHEREOF, the Parties have executed this Amendment as of the date first set forth above.

  

					
	 	 	Indevus Pharmaceuticals, Inc.
			
	 	 	By:	 	 /s/ Michael W. Rogers

	 	 	Name:	 	Michael Rogers
	 	 	Title:	 	EVP & CFO
		
	 	 	Odyssey Pharmaceuticals, Inc.
			
	 	 	By:	 	 /s/ Wayne P. Yetter

	 	 	Name:	 	Wayne Yetter
	 	 	Title:	 	CEO
	
	 PLIVA d.d. hereby guarantees the performance by Odyssey of its obligations under this Amendment No. 1, in accordance with Section 15.13 of the
Agreement:

		
	 	 	PLIVA d.d.
			
	 	 	By:	 	 /s/ Ivan Mijatovic

	 	 	Name:	 	Ivan Mijatovic
	 	 	Title:	 	CFO

 Appendix A 
 Phase IV Studies 
  
 SECURE Study

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00084-of-00352.parquet"}]]